HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EPA advisory committee

This article was originally published in The Rose Sheet

Executive Summary

Endocrine Disruptor Methods Validation Advisory Committee is being established by the EPA as a source of advice for the agency on matters related to the validation of assays under consideration by the Endocrine Disruptor Screening Program, EPA announces in June 2 Federal Register 1notice. The group will provide recommendations on "scientific and technical aspects of the assays as they progress through the validation process" and also will "provide a forum for a diverse group of individuals representing a broad range of interests and scientific expertise," agency says. In a separate Federal Register notice, EPA announced it will accept nominations of candidates to the committee until June 18...
Advertisement
Advertisement
UsernamePublicRestriction

Register

RS012185

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel